HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
MONDAY, Jan. 29, 2018 (HealthDay News) -- Magnetic resonance (MR) imaging is accurate in differentiating T1 or lower tumors from T2 or higher tumors among patients with bladder cancer, according to a review published in the February issue of Radiology.
Li Huang, M.D., Ph.D., from Sun Yat-Sen University in Guangzhou, China, and colleagues conducted a systematic literature review to identify studies evaluating the diagnostic accuracy of MR imaging for differentiating stage T1 or lower tumors from stage T2 or higher tumors in patients with bladder cancer. Additionally, studies assessing the influence of different imaging protocols in patients with bladder cancer were examined.
The researchers identified 17 studies totaling 1,449 patients with bladder cancer. Across studies, the pooled sensitivity of MR imaging was 0.90 and the specificity was 0.88 for differentiating tumors staged T1 or lower from those staged T2 or higher. Sensitivity (0.92) and specificity (0.96) were improved with diffusion-weighted imaging and use of higher field strengths (3 T).
"Our meta-analysis shows high sensitivity and specificity for MR imaging to differentiate T1 or lower tumors from T2 or higher tumors before surgery and that a 3.0-T device combined with diffusion-weighted imaging had the highest sensitivity and specificity in all studies," the authors write.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 28, 2022